Patients in whom symptoms remain refractory to H1-antihistamines should be referred to a dermatologist and/or clinical immunologist for review and initiation of second and third-line therapeutic agents. CSU follows a fluctuant disease course and may resolve spontaneously. Accordingly, efficacy and need for continuation of treatment should be evaluated periodically at 3- to- 6-month intervals.